



INVEST LIKE A PRO, WITH THE PROS!





www.capitalideasmedia.com

Morning Need to Know

Getting you ready for your investing day

August 26, 2019

**Written & compiled by Mark Bunting, Publisher,
Capital Ideas Media**



CANADIAN ANALYSTS' CALLS

INITIATIONS

Sundial Growers (NASDAQ:SNDL). CIBC starts coverage with a "neutral" rating and a price target of \$11 (U.S.) on the newly public company. The stock closed Friday at \$9.65. CIBC has provided investment banking services to SNDL within the last 12 months.

**

Cargojet (TSX:CJT). RBC boosts the target to \$136 (Canadian) from \$119. Cormark Securities lifts its target to \$120 from \$105.

And Echelon Wealth Partners raises the target to \$130 from \$120, which gives the stock a **projected return of about 27%**, after the company struck a deal with Amazon.com which would give the e-commerce giant as much 15% ownership of the overnight cargo company.

Echelon calls CJT *"the Amazon of the North"*.

After CJT's stock gained 12% on Friday, the shares are now higher since our December 18 cover story by 46%.

U.S. ANALYSTS' CALLS

INITIATIONS

Organogenesis Holdings (NASDAQ:ORGO).

Credit Suisse starts coverage on the regenerative medicine company with an "outperform" and a target of \$9 (U.S.).

**

Dish Network (NASDAQ:DISH) gets upgraded to "strong buy" at Raymond James, which says it's an opportune time to buy the stock.

STOCKS THAT MAY MOVE

Aimia (TSX:AIM) is selling about half of its investment in **Cardlytics (NASDAQ:CDLX)** for nearly \$45 million (Canadian).

Khiron Life Sciences (TSXV:KHRN) posted a Q2 net loss of \$10.6 million or 11 cents per share versus a net loss of \$6.2 million a year ago. Revenue was \$2.2 and adjusted EBITDA was a loss of \$7.7 million, compared to \$2.7 million a year earlier.

Interfor (TSX:IFP) said that long-time president and CEO Duncan Davies will step down at the end of the year and that senior VP and COO Ian Fillinger will take over.

Namaste Technologies (TSXV:N) has taken the interim tag off Meni Morim and named him as chief executive officer and a board member. This after the company's CFO recently stepped aside.

Morim has his work cut out as Namaste's stock has never recovered after the company fired previous CEO Sean Dollinger in February. Namaste closed Friday at 40 cents a share after peaking at more than \$3.40 last September.

Celgene Corp (NASDAQ:CELG) is selling its psoriasis drug Otezla for \$13.4 billion (U.S.) in cash to **Amgen (NASDAQ:AMGN)** in order to allay antitrust concerns in its \$74 billion takeover by **Bristol-Myers Squibb (NYSE:BMY)**.

Pitney Bowes (NYSE:PBI) is higher by 9% in pre-market trading as its selling its software solutions business to private enterprise software company Syncsort for \$700 million in cash.

Constellation Brands (NYSE:STZ) says its net loss from its ownership of Canopy Growth shares will be \$132.5 million over the six months ended August 31.

Target (NYSE:TGT) and **Disney (NYSE:DIS)** have struck a deal to setup Disney stores in dozens of

Target stores.

MARKETS

S&P/TSX and U.S. equity futures are sharply higher after U.S. President Donald Trump said China had reached out to re-open trade talks.

German business confidence fell to a seven-year low.

CURRENCIES

The Canadian dollar is inching lower \$0.7515 (U.S.).

COMMODITIES

West Texas Intermediate is up by 1.2% to \$54.81 a barrel.

Gold touched the \$1,550 an ounce mark overnight for the first time in six years before settling back to \$1,539.90.

DAILY UPDATE

Tomorrow's new [*Capital Ideas Digest*](#) uncovers a Canadian pharmaceutical company that's growing revenue at more than a 400% clip, is EBITDA positive, and should get way more attention than it does.

Please email questions, comments or concerns to: [*customercare@capitalideasresearch.com*](mailto:customercare@capitalideasresearch.com)

Access, insight and ideas.

Mark Bunting
Publisher,
Capital Ideas Media

www.capitalideasmedia.com



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[update subscription preferences](#)

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada